DNJ-20
DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL) . DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research[1].
Product Specifications
CAS Number
[3081926-49-7]
UNSPSC
12352005
Target
Glycosidase; SARS-CoV
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Field of Research
Infection; Inflammation/Immunology
Smiles
O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=C1C(OCCCCCCCCCCN4[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C4)=CC(O)=C3
Molecular Formula
C31H41NO10
Molecular Weight
587.66
References & Citations
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-173411/
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Glucosidase
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
